UBX - UNITY Biotech up 27% on mid-stage data from diabetic macular edema treatment
- UNITY Biotechnology ( NASDAQ: UBX ) is up 27% in premarket trading after releasing phase 2 data on diabetic macular edema candidate UBX1325 that met efficacy and safety endpoints .
- Results showed that after 24 weeks of a single dose, the mean change in best corrected visual acuity (BCVA) of treated patients was an increase of +6.2 ETDRS letters, representing an improvement of +7.6 ETDRS letters compared to placebo arm patients.
- Also, patients receiving UBX1325 maintained central subfield thickness ( CST ) while placebo patients saw a worsening of CST.
- The company plans to initiate a pivotal trial for the candidate in H2 2023.
- Check out why Seeking Alpha contributor LB Research considers UNITY ( UBX ) a hold.
For further details see:
UNITY Biotech up 27% on mid-stage data from diabetic macular edema treatment